회원 로그인 창


로그인 메뉴

따끈따끈! 신착 전자책

더보기

콘텐츠 상세보기
코로나-19 바이러스 : 급성 호흡 곤란 증후군의 치료


SMART
 

코로나-19 바이러스 : 급성 호흡 곤란 증후군의 치료

Valentina Giudice, Pasquale Pagliano, Alessandro Vatrella, Alfonso Masullo, Sergio Poto,외 | 아진

출간일
2020-07-12
파일형태
PDF
용량
9 M
지원 기기
PC
대출현황
보유1, 대출0, 예약중0
콘텐츠 소개
목차
한줄서평

콘텐츠 소개

To date, there are no specific therapeutic strategies for treatment of COVID-19.
Based on the hypothesis that complement and coagulation cascades are activated
by viral infection, and might trigger an acute respiratory distress syndrome
(ARDS), we report clinical outcomes of 17 consecutive cases of
SARS-CoV-2-related ARDS treated (N = 7) with the novel combination of
ruxolitinib, a JAK1/2 inhibitor, 10 mg/twice daily for 14 days and eculizumab, an
anti-C5a complement monoclonal antibody, 900 mg IV/weekly for a maximum of
three weeks, or with the best available therapy (N = 10). Patients treated with the
combination showed significant improvements in respiratory symptoms and
radiographic pulmonary lesions and decrease in circulating D-dimer levels
compared to the best available therapy group. Our results support the use of
combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related
ARDS by simultaneously turning off abnormal innate and adaptive immune
responses.

목차

제 1편 코로나바이러스 정의
1. 코로나바이러스감염증-19(Covid-19) 정보 7
2. 코로나바이러스 분류 및 특성 9
3. 코로나바이러스 전자현미경 형태 11
4. 코로나바이러스 구조 (Covid-19 Organization) 13
5. 코로나19: 환경에 지속적인 영향을 미칠까? 19
6. 치료법(Therapeutical Method) 22

제 2편 연구논문
Combination of Ruxolitinib and Eculizumab for Treatment of Severe
SARS-CoV-2-Related Acute Respiratory Distress Syndrome:
A Controlled Study

1. INTRODUCTION 23
2. METHODS 24
3. Statistical Analysis 25
4. RESULTS AND DISCUSSION 26
5. DATA AVAILABILITY STATEMENT 27
6. ETHICS STATEMENT 27
7. ACKNOWLEDGMENTS 27
8. REFERENCES 27

한줄서평

  • 10
  • 8
  • 6
  • 4
  • 2

(한글 300자이내)
리뷰쓰기
한줄 서평 리스트
평점 한줄 리뷰 작성자 작성일 추천수

등록된 서평이 없습니다.